Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270525 · ClinicalTrials.gov registry record · Phase 2
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
A Phase 2 study of COPD, sponsored by Verona Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT05270525 is a Phase 2 study of COPD that is actively recruiting participants, run by Verona Pharma. The registered enrollment target is 56 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05270525, a Phase 2 study of COPD, is actively recruiting participants, sponsored by Verona Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ensifentrine
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05270525
The ClinicalTrials.gov registry entry for NCT05270525 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (98% lower). The listed sponsor is Verona Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05270525 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05270525 about?
NCT05270525 is a clinical study titled "Effect of Ensifentrine on Sputum Markers of Inflammation in COPD". This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a tot...
What is the current status of trial NCT05270525?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-05-27. Estimated completion is 2027-06.
What conditions does trial NCT05270525 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT05270525?
The interventions under investigation include: Placebo (DRUG), Ensifentrine (DRUG).
Who is sponsoring clinical trial NCT05270525?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05270525 being conducted?
This trial has 3 study locations across Alabama, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
RECRUITING · Phase 2
-
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
COMPLETED · Phase 2
-
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.